Literature DB >> 16124759

Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene.

George R Pettit1, Collin R Anderson, Eric J Gapud, M Katherine Jung, John C Knight, Ernest Hamel, Robin K Pettit.   

Abstract

Further structure-activity relationship (SAR) exploration of 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene (1a) derivatives resulted in the efficient synthesis of tyrosine amide hydrochloride 9, two tyrosine amide phosphate prodrugs (3a and 6), and sodium aspartate amide 11. Two additional cancer cell growth inhibitors (14 and 16) were synthesized by employing peptide coupling between amine 1a and the Dap unit of dolastatin 10 (4a) to yield amide 14 followed by Dov-Val-Dil (15) to yield peptide 16. The latter represents a combination of stilbene 1a with the des-Doe tetrapeptide unit of the powerful tubulin assembly inhibitor dolastatin 10. Peptide 16 was examined for potential binding to tubulin in the vinca and/or colchicine regions and found to perform primarily as a relative of dolastatin 10. Amide 14 had anticryptococcal and antibacterial activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124759      PMCID: PMC3335365          DOI: 10.1021/np058033l

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  31 in total

Review 1.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Authors:  Ernest Hamel
Journal:  Cell Biochem Biophys       Date:  2003       Impact factor: 2.194

2.  Combination bacteriolytic therapy for the treatment of experimental tumors.

Authors:  L H Dang; C Bettegowda; D L Huso; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

3.  Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.

Authors:  Lingyun Li; Amyn M Rojiani; Dietmar W Siemann
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

4.  The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas.

Authors:  Hans Petter Eikesdal; Willy Landuyt; Olav Dahl
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

5.  Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs.

Authors:  G R Pettit; B R Moser; M R Boyd; J M Schmidt; R K Pettit; J C Chapuis
Journal:  Anticancer Drug Des       Date:  2001 Aug-Oct

6.  The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

7.  Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.

Authors:  Daniel A Beauregard; R Barbara Pedley; Sally A Hill; Kevin M Brindle
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

8.  Guanosine 5'-O-(3-thiotriphosphate), a potent nucleotide inhibitor of microtubule assembly.

Authors:  E Hamel; C M Lin
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

9.  Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene and derived amino acid amides.

Authors:  George R Pettit; Collin R Anderson; Delbert L Herald; M Katherine Jung; Debbie J Lee; Ernest Hamel; Robin K Pettit
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

10.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Authors:  Afshin Dowlati; Kelly Robertson; Matthew Cooney; William P Petros; Michael Stratford; John Jesberger; Niusha Rafie; Beth Overmoyer; Vinit Makkar; Bruce Stambler; Anne Taylor; John Waas; Jonathan S Lewin; Keith R McCrae; Scot C Remick
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  2 in total

Review 1.  Bioavailability challenges associated with development of anti-cancer phenolics.

Authors:  Song Gao; Ming Hu
Journal:  Mini Rev Med Chem       Date:  2010-06       Impact factor: 3.862

Review 2.  Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Manicka V Vadhanam
Journal:  Cancer Lett       Date:  2013-02-19       Impact factor: 8.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.